Where does Daiichi Sankyo Company, Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Daiichi Sankyo Company, Limited ranks #1,391 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Daiichi Sankyo Company, Limited hold?

Daiichi Sankyo Company, Limited holds 302 US utility patents granted between 2015 and 2025, spanning 31 technology areas.

What is Daiichi Sankyo Company, Limited's Innovation Score?

Daiichi Sankyo Company, Limited has an Innovation Score of 56.1 out of 100 (top 6% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Daiichi Sankyo Company, Limited's patent grant rate increasing or decreasing?

Daiichi Sankyo Company, Limited's recent grant velocity is -26% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Daiichi Sankyo Company, Limited's patents?

Daiichi Sankyo Company, Limited's patents average 18.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Daiichi Sankyo Company, Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Daiichi Sankyo Company, Limited

Q: What technology areas does Daiichi Sankyo Company, Limited focus on?

Daiichi Sankyo Company, Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 259 patents. Grants appear in 31 CPC subclasses total.

USPTO PatentsView assignee record - 302 granted patents across 31 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Daiichi ranks #1,391 of 49,997 tracked US assignees by granted-patent volume, with 302 patents across 31 technology areas.

#1,391
of 49,997 US assignees by volume: Top 6%
by Innovation Score (56.1/100): 18.8
avg claims per patent: -26%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1391 · Foreign Corporation #1,391 · 302 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 302 grants
TOP-DECILE #1,391/49,997
PHOTO-FINISH Assistance PUBLIQUE—…
CPC-FOCUS A61P · 31 areas
INNOV-PAR 56.1/100
CLAIMS-RICH 18.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -26% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Assistance PUBLIQUE—HÔPITAUX DE Paris (APHP) (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Daiichi Sankyo · this assignee

56
Dupont Nutrition… · near

56
Electricite DE France · near

56
Gaztransport ET… · near

56
Liebherr-aerospace… · near

56
3D Lighting… · lowest

7

What this shows Daiichi's Innovation Score is 56.1/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Daiichi's grants concentrate

Daiichi Sankyo Company, Limited is a focused PatentsView assignee: 31 CPC subclasses with 85.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (43 grants) versus a trough of 15 in 2023. By volume, Daiichi sits between Verint Americas Inc. and Neoperl GMBH.

Daiichi's three-year grant acceleration

From 2019–2021 to 2022–2024, Daiichi Sankyo Company, Limited moved from 83 to 67 grants (0.81x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,821. See the growth leaderboard.

Verint Americas

303
Assistance Publiq…

302
Beijing Didi Infi…

302
Briggs & Stratton

302
ETA Manufacture H…

302
Hitachi Industria…

302
Hall Labs

302
Neoperl

302
Daiichi Sankyo ◀

302

What this shows Daiichi holds 302 patents at rank #1,391, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Daiichi

By rank, the assignees closest to #1,391 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Daiichi's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Daiichi, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (56 here).

Electricite DE France 56 Dupont Nutrition Biosciences APS 56 Gaztransport ET Technigaz 56 Liebherr-aerospace Toulouse SAS 56

Similar claim depth

Nearest assignees by average claims per patent (18.8 here).

The Governing Council of the University of Toronto 18.8 avg OpenTV, Inc. 18.8 avg Koninklijke Philips Electronics NV 18.8 avg Li-cor, Inc. 18.8 avg

Daiichi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Daiichi Sankyo Company, Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	43	14.2%
2016	23	7.6%
2017	39	12.9%
2018	32	10.6%
2019	28	9.3%
2020	24	7.9%
2021	31	10.3%
2022	26	8.6%
2023	15	5.0%
2024	26	8.6%
2025partial year	15	5.0%

Which technologies does Daiichi Sankyo Company, Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 259

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 220

C07D - Heterocyclic Compounds 129

C07K - Peptides 112

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 65

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 47

C07C - Acyclic OR Carbocyclic Compounds 37

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 32

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 22

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 21

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 13

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 9

Y02A - Technologies FOR Adaptation TO Climate Change 9

C12Y - Enzymes 9

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 8

Top 15 of 31 technology areas

Where it ranks

Overall rank by patents

#1,391

of 49,997 tracked assignees

Innovation Score

56.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Daiichi Sankyo Company, Limited's patent record in context - here's where to go next.

Daiichi Sankyo Company, Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,391 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Daiichi Sankyo Company, Limited against Verint Americas Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 56.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.